Literature DB >> 15592478

Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus.

Aymeric de Parseval1, Udayan Chatterji, Garrett Morris, Peiqing Sun, Arthur J Olson, John H Elder.   

Abstract

CD134 is a primary binding receptor for feline immunodeficiency virus (FIV), and with CXCR4 facilitates infection of CD4(+) T cells. Human CD134 fails to support FIV infection. To delineate the regions important for defining virus specificity of CD134, we exchanged domains between human and feline CD134. The binding site for FIV surface glycoprotein (SU) is located in domain 1, in a region distinct from the natural ligand (CD134L)-binding site. Mutagenesis showed that Asp60 and Asp62 are required for interaction with FIV, and modeling studies localized these two residues to the outer edge of domain 1. Substitutions S60D and N62D, in conjunction with H45S, R59G and V64K, imparted both FIV SU binding and receptor function to human CD134. Finally, we demonstrated that soluble CD134 facilitates infection of CD134(-) CXCR4(+) target cells in a manner analogous to CD4 augmentation of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592478     DOI: 10.1038/nsmb872

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  33 in total

1.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 2.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 3.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

4.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

5.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

Review 6.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

7.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

Review 8.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein.

Authors:  Qiong-Ying Hu; Elizabeth Fink; Yang Hong; Cathy Wang; Chris K Grant; John H Elder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

10.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.